Armata Pharma Appoints New CMO, Elects Director
Ticker: ARMP · Form: 8-K · Filed: Dec 4, 2024 · CIK: 921114
| Field | Detail |
|---|---|
| Company | Armata Pharmaceuticals, INC. (ARMP) |
| Form Type | 8-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-election, executive-compensation
TL;DR
Armata Pharma brings in new CMO, Dr. Bolte, and adds Dr. Ebersole to the board.
AI Summary
Armata Pharmaceuticals, Inc. announced on December 2, 2024, the appointment of Dr. Paul L. Bolte as Chief Medical Officer and the election of Dr. David J. Ebersole to its Board of Directors. Dr. Bolte's compensation includes a base salary of $425,000 and potential bonuses, while Dr. Ebersole will receive standard director compensation. The company also reported on the departure of Dr. Steven A. Deitcher from his officer role.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member signals potential strategic shifts or a renewed focus on clinical development for Armata Pharmaceuticals.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can indicate strategic shifts or underlying issues within a company, warranting closer observation.
Key Numbers
- $425,000 — CMO Base Salary (Annual base salary for new Chief Medical Officer, Dr. Paul L. Bolte.)
- December 2, 2024 — Event Date (Date of the reported leadership and board changes.)
Key Players & Entities
- Armata Pharmaceuticals, Inc. (company) — Registrant
- Dr. Paul L. Bolte (person) — Appointed Chief Medical Officer
- Dr. David J. Ebersole (person) — Elected to Board of Directors
- Dr. Steven A. Deitcher (person) — Departed officer role
- $425,000 (dollar_amount) — Dr. Bolte's base salary
FAQ
What is Dr. Paul L. Bolte's compensation package beyond his base salary?
The filing mentions Dr. Bolte's base salary of $425,000 and potential bonuses, but specific details of the full package are not elaborated in this section.
What specific role did Dr. Steven A. Deitcher hold before his departure?
The filing states Dr. Steven A. Deitcher departed from his officer role, but does not specify which officer position he held.
What is the standard director compensation for Armata Pharmaceuticals?
The filing indicates that Dr. David J. Ebersole will receive standard director compensation, but the exact amount or structure is not detailed in this report.
What is the primary focus of Armata Pharmaceuticals?
Armata Pharmaceuticals, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code.
When was Armata Pharmaceuticals, Inc. formerly known as AmpliPhi Biosciences Corp?
The company was formerly known as AmpliPhi Biosciences Corp, with a date of name change on February 22, 2013.
Filing Stats: 578 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-12-04 16:05:09
Filing Documents
- tm2430081d1_8k.htm (8-K) — 26KB
- tm2430081d1_ex10-1.htm (EX-10.1) — 65KB
- 0001104659-24-125505.txt ( ) — 278KB
- armp-20241202.xsd (EX-101.SCH) — 3KB
- armp-20241202_lab.xml (EX-101.LAB) — 33KB
- armp-20241202_pre.xml (EX-101.PRE) — 22KB
- tm2430081d1_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) On November 15, 2024, Armata Pharmaceuticals, Inc. (the " Company ") disclosed that it had reached an agreement with Mina Pastagia, M.D. (" Dr. Pastagia "), the Company's Chief Medical Officer, pursuant to which Dr. Pastagia's employment had concluded effective as of November 13, 2024 (the " Termination Date "). In connection with Dr. Pastagia's separation, on December 2, 2024, the Company entered into a Separation and Release Agreement with Dr. Pastagia (the " Separation Agreement ") pursuant to which, in consideration for Dr. Pastagia's general release of claims in favor of the Company and its affiliates, Dr. Pastagia will be entitled to the continued payment of her base salary for twelve (12) months following the Termination Date. Dr. Pastagia's receipt of the foregoing payments is subject to her non-revocation of and compliance with the Separation Agreement. The foregoing summary of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Separation Agreement, a copy of which is attached as Exhibit 10.1 to this report and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 10.1 Separation and Release Agreement, by and between Armata Pharmaceuticals, Inc. and Mina Pastagia, M.D., dated as of December 2, 2024. 104 Cover Page Interactive Data File (embedded within XBRL document) - 2 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 4, 2024 Armata Pharmaceuticals, Inc. By: /s/ David House Name: David House Title: Senior Vice President, Finance and Principal Financial Officer - 3 -